TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets

The Therapeutic Intensification in De Novo Leukaemia (TIDEL)-II study enrolled 210 patients with chronic phase chronic myeloid leukemia (CML) in two equal, sequential cohorts. All started treatment with imatinib 600 mg/day. Imatinib plasma trough level was performed at day 22 and if <1000 ng/mL,...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Blood
Главные авторы: Yeung, David T., Osborn, Michael P., White, Deborah L., Branford, Susan, Braley, Jodi, Herschtal, Alan, Kornhauser, Michael, Issa, Samar, Hiwase, Devendra K., Hertzberg, Mark, Schwarer, Anthony P., Filshie, Robin, Arthur, Christopher K., Kwan, Yiu Lam, Trotman, Judith, Forsyth, Cecily J., Taper, John, Ross, David M., Beresford, Jennifer, Tam, Constantine, Mills, Anthony K., Grigg, Andrew P., Hughes, Timothy P.
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Hematology 2015
Предметы:
Clinical Trials and Observations
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5161008/
https://ncbi.nlm.nih.gov/pubmed/25519749
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-07-590315
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы